What's Happening?
Agenus Inc. will host a virtual Stakeholder Briefing on October 21, 2025, featuring updates on its immunotherapy combination botensilimab (BOT) and balstilimab (BAL). The briefing will include insights
from leading experts on clinical progress and international access, with discussions on recent data from the European Society for Medical Oncology (ESMO) Congress 2025. The session will highlight BOT/BAL's inclusion in France's Autorisation d'Accès Compassionnel (AAC) program, expanding access for patients with refractory MSS colorectal cancer.
Why It's Important?
The Stakeholder Briefing represents an opportunity for Agenus to showcase its advancements in immunotherapy, particularly the global momentum of BOT/BAL. By expanding access through programs like France's AAC, Agenus aims to enhance treatment options for patients with refractory cancers, potentially improving outcomes and quality of life. The briefing underscores the importance of international collaboration and regulatory support in advancing innovative cancer therapies.
What's Next?
Agenus plans to continue its Stakeholder Briefing Series, with a third session scheduled for November. The company will focus on BOT/BAL's progress and corporate milestones, potentially leading to further clinical developments and expanded access. Agenus may also explore additional international partnerships and regulatory pathways to enhance its immunotherapy offerings.
Beyond the Headlines
The briefing highlights the role of stakeholder engagement in advancing healthcare innovation, offering a platform for dialogue and collaboration between industry leaders, researchers, and regulatory bodies. By fostering transparency and communication, Agenus aims to build trust and support for its immunotherapy initiatives, driving progress in cancer treatment and patient care.
